New Risk • May 18
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$134k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$134k free cash flow). Shares are highly illiquid. Negative equity (-US$1.8m). Revenue is less than US$1m. Market cap is less than US$10m (CA$12.8m market cap, or US$9.31m). Duyuru • Jan 28
Biomind Labs Inc. announced that it expects to receive CAD 2.52 million in funding Biomind Labs Inc. announced a non-brokered private placement of up to 28,000,000 units at a price of CAD 0.09 per unit for gross proceeds of up to CAD 2,520,000 on January 27, 2026. Each unit will be composed of one common share and one common share purchase warrant. Each warrant will entitle the holder thereof to acquire one common share at a price of CAD 0.12for a period of 24 months following the completion of the offering. The offering is expected to close on or about February 6, 2026, and is subject to customary closing conditions, including all necessary regulatory approvals. Securities issued under the offering will be subject to a statutory hold period of four months and one day from the date of issuance. The company may also pay finders' fees to certain eligible finders in accordance with applicable securities laws and the policies of CBOE Canada. Duyuru • Dec 11
Biomind Labs Inc., Annual General Meeting, Feb 04, 2026 Biomind Labs Inc., Annual General Meeting, Feb 04, 2026. Board Change • Dec 11
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Scott Ackerman was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Nov 19
Biomind Labs Inc. Appoints Scott Ackerman as an Independent Director of the Board of Directors, and as an Independent Member of the Audit Committee Biomind Labs Inc. announced that Scott Ackerman has been appointed as an independent director of the Board of Directors of the Company, and as an independent member of the Company's Audit Committee. Mr. Ackerman is the CEO of Emprise Capital Corp., a private merchant bank providing restructuring services to public companies for over 20 years, and is also a director, senior officer, and chair of a number of audit committees for several Canadian listed public companies. Board Change • Mar 17
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). CFO & Director Oscar León Bentancor was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Jan 30
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). CFO & Director Oscar León Bentancor was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Jan 14
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). CFO & Director Oscar León Bentancor was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. New Risk • Nov 28
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (74% average weekly change). Negative equity (-US$1.1m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (CA$33.4m market cap, or US$23.8m). Duyuru • Jul 19
Biomind Labs Inc. Announces the Decision to Advance A New Phase II Clinical Trial Biomind Labs Inc. announced the decision to advance a new Phase II clinical trial. This decision follows new and unexpected findings from a pre-clinical study of its proprietary compound 3,4,5-trimethoxyphenethylamine-based BMND06. The toxicological studies reveal that the BMND06 candidate is physiologically safe, exhibiting low acute and chronic oral toxicity with no mutagenic effects. The primary objective was to establish a starting safe dose for the first-in-human trial and evaluate the potential toxicity of BMND06. In addition to in vivo studies, in vitro assays surprisingly demonstrated that BMND06 significantly reduces LPS (lipopolysaccharide)-induced IL-6 (interleukin-6) levels in various colon cancer cell lines, outperforming dexamethasone-a commonly used anti-inflammatory corticosteroid-by fivefold in reducing IL-6 induction caused by LPS. Obesity is the accumulation of abnormal or excessive fat that can interfere with maintaining optimal health. Excess macronutrients in adipose tissue stimulate the release of inflammatory mediators such as tumor necrosis factor-alpha (TNF-a) and interleukin 6 (IL-6), while reducing adiponectin production, leading to a pro-inflammatory state and oxidative stress. Elevated IL-6 levels prompt the liver to synthesize and secrete C-reactive protein (CRP). As a risk factor, inflammation is a key mechanism in the development of cardiovascular diseases, including coagulation disorders, atherosclerosis, metabolic syndrome, insulin resistance, and diabetes mellitus. It is also linked to non-cardiovascular diseases such as psoriasis, depression, cancer, and renal disease. Overweight and obesity have serious social and psychological consequences for those affected. The preclinical studies have provided robust scientific evidence supporting the safety and anti-inflammatory efficacy of the active pharmaceutical ingredient of BMND06. This data justifies advancing to a Phase II New Drug Clinical Trial in humans, focusing on obesity, without the need for additional preclinical assays. Board Change • Jun 04
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Director Ben M. Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Board Change • Dec 07
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Ben M. Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. New Risk • Dec 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.7m free cash flow). Shares are highly illiquid. Negative equity (-US$638k). Revenue is less than US$1m. Market cap is less than US$10m (CA$10.1m market cap, or US$7.48m). Minor Risk Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Board Change • Nov 24
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Ben M. Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. New Risk • Nov 07
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$10.3m (US$7.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.7m free cash flow). Shares are highly illiquid. Negative equity (-US$638k). Revenue is less than US$1m. Market cap is less than US$10m (CA$10.3m market cap, or US$7.48m). Board Change • Nov 07
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Ben M. Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Oct 20
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Ben M. Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Duyuru • Sep 15
Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications Biomind Labs Inc. announced the successful completion of the first 5-Metoxi-N,N-dimethyltryptamine ("5-MeO-DMT") organic synthesis scheme. Key accomplishments of the first 5-MeO-DMT organic synthesis scheme include: Organic Synthesis Success: A pioneering organic synthesis scheme that enables the efficient production of 5-MeO-D MT freebase. This novel process ensures high purity and maintains the compound's integrity, making it suitable for pharmaceutical applications. Pharmaceutical-Grade Quality: The 5-MeO-DMD freebase produced using this new method and under Good Manufacturing Practices (GMP) meets stringent pharmaceutical standards, guaranteeing its suitability for use in the development of advanced medicines and therapies. Potential Therapeutic Applications: The availability of high-purity 5-MeO-DCT as an API paves the way for innovative research and development in various therapeutic areas. Although Biomind primarily targets the treatment of mental health disorders, such as depression and anxiety, other areas of medicine could benefit from the availability of high-purity5-MeO-D MT. Commitment to Safety and Compliance: Biomind places an emphasis on safety and compliance with regulatory standards. The Company has undertaken rigorous testing and quality control measures to ensure the levels of product safety and consistency. Additionally, the associated complexities in the authorization process, substantial expenses, and intricate logistics further compound these challenges. Board Change • Aug 25
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Ben Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Jun 23
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Ben Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Feb 10
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Ben Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Duyuru • Dec 29
Biomind Labs Inc. Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate Bmnd08 for Depression and Anxiety in Alzheimer’s Disease Biomind Labs Inc. announced that it has successfully completed the development of a novel sublingual formulation to be used in the Phase II trial for its 5-Metoxi-N,N-dimethyltryptamine (“5-MeO-DMT”)-based BMND08 candidate for the potential treatment of depression and anxiety in Alzheimer’s disease. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Fraser Buchan was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Nov 15
Biomind Labs Inc. Announces FDA Investigational New Drug Clearance for its New Chemical Entity Triptax™ Targeting Treatment-Resistant Depression Biomind Labs Inc. announced that the U.S. Food and Drug Administration (“FDA”) has given the Company Investigational New Drug (“IND”) clearance related to the Company’s New Chemical Entity (“NCE”) Triptax™. Duyuru • Nov 05
Biomind Labs Inc. Announces Positive Initial Results From Its Phase II Trial on its BMND01 Candidate for Treatment Resistant Depression Biomind Labs Inc. announced positive initial results from part I of its Phase II trial on its BMND01 candidate, a novel liquid inhaled formulation of N,N-Dimethyltryptamine (DMT) for Treatment-Resistant Depression (TRD). The trial, led by Professor Dráulio Araújo, Ph.D., has involved a dose exploration schedule ranging from 5 to 100 mg. No volunteer presented serious adverse events or clinical risk to the 11 different doses tested. The experimental design of this open-label ascending dose trial involved developing and implementing a proprietary clinical-experimental protocol based on the fundamentals of interventional psychiatry. This multidisciplinary approach combines a psychiatric procedure for dosing DMT associated with psychological support under strict clinical standards. Duyuru • Oct 12
Biomind Labs Announces Pre-Ind Meeting Request Granted by FDA for Its New Chemical Entity Triptax Targeting Treatment-Resistant Depression Biomind Labs Inc. announced a Pre-Investigational New Drug (“Pre-IND”) meeting granted by the U.S. Food and Drug Administration (the “FDA”) for the Company’s new chemical entity (“NCE”) Triptax™. The Company has submitted a briefing package to the Division of Psychiatry, Center for Drug Evaluation and Research at the FDA, and awaits further feedback on the NCE Triptax™. The Pre-IND meeting is a critical step in the U.S. regulatory approval process that provides an opportunity for the Company and the FDA to discuss the NCE development plan and to obtain the FDA’s guidance for new clinical trials the Company may conduct on the NCE Triptax™. Duyuru • Sep 28
Biomind Labs and Queen's University of Belfast Receives Controlled Substances License to Commence the Production of A Novel Transdermal Drug Delivery System Biomind Labs Inc. announced the receipt of a Controlled Substances License and the commencement of an eight-month project to produce and evaluate novel rapidly-dissolving and sustained-release hydrogel-forming microneedle arrays designed for the transdermal delivery of Biomind’s key psychedelic compounds: N, N-dimethyltryptamine (“DMT”), 5-methoxyN,N-dimethyltryptamine (“5-MeO-DMT”) and mescaline. The use of polymeric microneedle array patches (“MAPs”) is an attractive way of delivering drugs through the skin. Upon MAP application, microneedles painlessly penetrate the outer layer of the skin, creating temporary microchannels in this highly effective barrier to diffusion, through which enhanced transdermal drug delivery can be achieved. Given the presence of a dense network of blood vessels in the deeper layers of the skin, drugs can be absorbed into the plasmatic circulation and distributed to the entire body, producing a systemic effect. Additional advantages of this technology, such as the avoidance of first-pass metabolism and drug delivery in a rate-controlled or long-acting manner, can serve to reduce the incidence of side-effects and dosing frequency, which in turn may lead to increased treatment adherence. Duyuru • Sep 22
Biomind Labs Announces Completion of Dosing in Phase II Trial of its DMT-Based Inhaled Formulation Bmnd01 for Treatment-Resistant Depression Biomind Labs Inc. announced the completion of dose administration of 30 healthy subjects in the Company’s Phase II trial of its novel drug candidate BMND01 for Treatment-Resistant Depression. 10% to 30% of people with depression exhibit treatment-resistant symptoms coupled with difficulties in social and occupational function, decline of physical health, poor quality of life, suicide ideation and attempts, self-injurious behavior, high relapse rate and increased health care utilization. The objectives of the trial are to establish the safety and tolerability of DMT. In addition to evaluating side effects, thistrial will also allow Biomind to explore the origin of the observed side effects, given that different associated physiological, behavioral, and cognitive markers will be collected before, during, and after the trial. Board Change • Jul 07
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Fraser Buchan was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Jun 08
Biomind Labs Inc., Annual General Meeting, Jun 28, 2022 Biomind Labs Inc., Annual General Meeting, Jun 28, 2022, at 10:00 US Eastern Standard Time. Agenda: To receive the audited financial statements of the Corporation for the financial year ended December 31, 2021, together with the report of the auditor thereon; to appoint MNP LLP, Chartered Professional Accountants, as auditor of the Corporation for the ensuing year and to authorize the directors of the Corporation to fix the remuneration of the auditor; to elect the directors of the Corporation for the ensuing year; and to transact such other business as may properly be brought before the Meeting or any adjournment or adjournments thereof. Duyuru • May 27
Biomind Labs Inc. Receives Approval for A Third Phase II Clinical Trial for Its 5-Meo-Dmt Based Bmnd08 Candidate for Treatment of Depression and Anxiety in Alzheimer’s Disease Biomind Labs Inc. announced that a third Phase II clinical trial for its BMND08 candidate based on 5-Methoxy-N,N-dimethyltryptamine (“5-MeO-DMT”) for treatment of depression and anxiety in patients with Alzheimer’s-type cognitive impairment has been approved by the Argentinian Institutional Review Board. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Fraser Buchan was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Apr 27
Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression Biomind Labs Inc. announced that it has commenced dose administration of the first subject in a Phase I/IIa clinical trial of the Company’s novel drug candidate BMND01, for treatment-resistant depression with inhaled administration. The Phase I/IIa clinical trial on Biomind's first innovative formulation of N,N-Dimethyltryptamine (“DMT”) is evaluating the safety, pharmacokinetics, behavioral and brain effects of BMND01, for inhaled administration. The trial has commenced on time and as scheduled and is being administered by superior medical practices at Biomind's new clinical psychedelic research facility in the University Hospital Onofre Lopes. Led by Dr. Dráulio Araújo, Biomind’s Scientific and Clinical advisor, the team is a renowned group of scientists that conducted the first randomized placebo-controlled trial with ayahuasca for treatment-resistant depression. Duyuru • Mar 05
Biomind Labs Inc. Announces Positive Results on in Vivo Studies for its Proprietary Drug Candidate BMND07 Biomind Labs Inc. announced positive results from in vivo studies. Biomind Labs’ BMND07 drug candidate, a novel DMT combination drug, proved to be physiologically safe, showing low acute oral toxicity and no mutagenic effect in all administered dosages in animals. Duyuru • Nov 25
Biomind Labs Inc. Announces Design of a Pharmaceutical Form for Psychedelic Drug Delivery Using 3D Printing Biomind Labs Inc. announced the successful design of an oromucosal solid pharmaceutical form obtained by 3D printing using selective laser sintering. The form contains as its active ingredients certain psychedelic molecules that the Company has in its portfolio of psychedelic candidates. This pharmaceutical form is aimed at alleviating neurological and psychiatric disorders, and acting as an anti-inflammatory agent for various inflammatory disorders. Duyuru • Oct 01
Biomind Labs Files International Patent Application on its DMT Candidates Across 153 Global Jurisdictions Biomind Labs Inc. announced that it has filed an international patent application that brings the potential to obtain patent coverage in 153 countries. This innovative technology, designed by the scientific team, has the potential to provide new levels of safety for both the patients and also the physicians who will be prescribing these medications. The company view this technology as marking a new concept within the psychedelic industry to increase the quality of treatments while ensuring their traceability. The objective is to provide the confidence that health agencies and government authorities require to start supporting this disruptive way of treating conditions such as depression, anxiety, addictive disorders, eating disorders and chronic pain, among others. Board Change • Sep 03
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Ravi Sood was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 